<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818064</url>
  </required_header>
  <id_info>
    <org_study_id>NN8226-3703</org_study_id>
    <secondary_id>2008-005529-13</secondary_id>
    <secondary_id>EudraCT No: 2008-005529-13</secondary_id>
    <nct_id>NCT00818064</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Single- Dose, Dose-escalation Trial of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this clinical trial is to investigate the
      safety and tolerability of single doses of Anti-IL-20 in healthy volunteers (HV) and patients
      with rheumatoid arthritis (RA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, including injection site tolerability</measure>
    <time_frame>during treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal serum half-life (tÂ½)</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum serum concentration (tmax)</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC0-t and AUC)</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relevant biomarkers in serum and plasma, as well as synovial fluid (if applicable)</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Inflammation</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A, HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose cohort 1 (3 subjects active, 1 placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B, HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose cohort 2 (3 subjects active, 1 placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C, HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose cohort 3 (3 subjects active, 1 placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D, HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose cohort 4 (3 subjects active, 1 placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E, HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose cohort 5 (3 subjects active, 1 placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A, RA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose cohort 1 (3 subjects active, 1 placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B, RA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose cohort 2 (3 subjects active, 1 placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C, RA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose cohort 3 (3 subjects active, 1 placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-IL-20</intervention_name>
    <description>Single s.c. injection (per dose cohort)</description>
    <arm_group_label>A, HV</arm_group_label>
    <arm_group_label>B, HV</arm_group_label>
    <arm_group_label>C, HV</arm_group_label>
    <arm_group_label>D, HV</arm_group_label>
    <arm_group_label>E, HV</arm_group_label>
    <arm_group_label>A, RA</arm_group_label>
    <arm_group_label>B, RA</arm_group_label>
    <arm_group_label>C, RA</arm_group_label>
    <other_name>NN8226</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single s.c. injection (per dose cohort)</description>
    <arm_group_label>B, HV</arm_group_label>
    <arm_group_label>C, HV</arm_group_label>
    <arm_group_label>D, HV</arm_group_label>
    <arm_group_label>E, HV</arm_group_label>
    <arm_group_label>A, RA</arm_group_label>
    <arm_group_label>B, RA</arm_group_label>
    <arm_group_label>C, RA</arm_group_label>
    <arm_group_label>A, HV</arm_group_label>
    <other_name>NN8226</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For healthy volunteers (HV) the following applies:

          -  Subjects who are considered to be generally healthy based on assessment of medical
             history, physical examination and clinical laboratory data at screening, as judged by
             the Investigator

          -  Females who are post-menopausal, surgically sterile or of non-child-bearing potential

          -  For rheumatoid arthritis (RA) patients the following applies:

          -  A diagnosis of rheumatoid arthritis according to the American College of Rheumatology
             (ACR1987 classification) of at least three months' duration prior to dosing

          -  Active RA, characterised by a Disease Activity Score 28 (DAS28) greater than 3.2

          -  Methotrexate treatment (stable doses of maximally 25.0 mg/week for at least 4 weeks)
             and concomitant intake of folic acid 1 mg/day or 5 mg/week

          -  Females who are post-menopausal, surgically sterile or of non-child-bearing potential

        Exclusion Criteria:

          -  For healthy volunteers (HV) the following applies:

          -  Male subjects who do not accept to use double barrier methods of birth control from
             first dosing until 3 moths after their last visit

          -  Body mass index (BMI) below 18.5 or above 35.0 kg/m2

          -  Clinically significant cardiac or cardiovascular disease

          -  Abnormal blood pressure and heart rate

          -  Hepatic insufficiency

          -  Renal insufficiency

          -  Positive for humane immunodeficiency virus (HIV)

          -  Positive for hepatitis B (HBV) or hepatitis C (HCV)

          -  Lymphoproliferative disease

          -  History or signs of malignancy (except adequately treated and cured basal or squamous
             cell carcinoma of the skin or cervical carcinoma in situ occurring more than 12 months
             prior to dosing)

          -  History of any autoimmune or current inflammatory conditions including rheumatoid
             arthritis or any other joint disease

          -  Active or latent tuberculosis: For tuberculosis unvaccinated subjects detected as a
             positive Mantoux test. For subjects vaccinated against tuberculosis detected as a
             positive QuantiFeron-test

          -  Chronic or ongoing infectious disease requiring systemic anti-infectious treatment
             within the last 2 weeks prior to administration of trial drug

          -  Any vaccination within the last month before dosing

          -  Known active viral, bacterial or fungal infection, including herpes, herpes zoster or
             cold sores 14 days prior to dosing

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements within 2 weeks prior to dosing, unless in the opinion of the Investigator
             the medication will not interfere with the trial procedures or compromise the safety
             of the subject

          -  History of or current drug and/or alcohol abuse

          -  Blood donation within the last 3 months (more than 0.45 L)

          -  For rheumatoid arthritis (RA) patients the following applies:

          -  Male subjects who do not accept to use double barrier methods of birth control from
             first dosing until 3 months after their last visit

          -  Body mass index (BMI) below 18.5 or above 35.0 kg/m2

          -  Subjects with chronic inflammatory autoimmune disease other than rheumatoid arthritis
             (except secondary SjÃ¶gren's syndrome)

          -  History of or current inflammatory joint disease other than rheumatoid arthritis (e.g.
             gout, psoriatic or reactive arthritis, Lyme's disease, juvenile arthritis)

          -  Chronic or ongoing infectious disease requiring systemic anti-infectious treatment
             within the last 2 weeks prior to dosing

          -  Any vaccination within the last month before dosing

          -  Known active viral, bacterial or fungal infection, including herpes, herpes zoster or
             cold sores 14 days prior to administration of trial product

          -  Lymphoproliferative disease

          -  History or signs of malignancy (except adequately treated and cured basal or squamous
             cell carcinoma of the skin or cervical carcinoma in situ occurring more than 12 months
             prior to dosing)

          -  Use of selective cyclooxygenase-2 (COX-2) inhibitors within the last 2 weeks prior to
             randomisation

          -  Concomitant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Lundblad MS, Overgaard RV, GÃ¶thberg M, Fjording MS, Watson E. Clinical pharmacokinetics of the anti-interleukin-20 monoclonal antibody NNC0109-0012 in healthy volunteers and patients with psoriasis or rheumatoid arthritis. Adv Ther. 2015 Mar;32(3):228-38. doi: 10.1007/s12325-015-0191-7. Epub 2015 Mar 7.</citation>
    <PMID>25749867</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2008</study_first_submitted>
  <study_first_submitted_qc>January 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2009</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

